ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced its participation in investor conferences in November, including the Jefferies London Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference. The company will be hosting fireside chats and webcasts of the discussions and presentations will be available through the investor section of the company’s website at www.oricpharma.com.

SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in November:

• Jefferies London Healthcare Conference – Participating in a fireside chat on Thursday, November 16, 2023, at 10:00 a.m. GMT
  
• 6th Annual Evercore ISI HealthCONx Conference – Participating in a fireside chat on Tuesday, November 28, 2023, at 10:25 a.m. ET
  

Webcasts of the discussions and presentations will be available through the investor section of the company’s website at www.oricpharma.com. Replays of webcasts will be available for 90 days following the events.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, (2) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

 

FAQ

What is the purpose of ORIC Pharmaceuticals, Inc.'s participation in the investor conferences in November?

ORIC Pharmaceuticals, Inc. is participating in the investor conferences to host fireside chats and present discussions on its developments in oncology treatments.

Where can the webcasts of the discussions and presentations be accessed?

The webcasts will be available through the investor section of the company’s website at www.oricpharma.com.

For how long will the replays of the webcasts be available?

Replays of webcasts will be available for 90 days following the events.